M42 Signals Expansion into Saudi Arabia with the Launch ofM42 Saudi Arabia, Deepening its Long-Standing PartnershipM42 formalizes its 12-year presence in the Kingdom at the Global Health Exhibition inRiyadh, reinforcing alignment with Vision 2030 and commitment to preventive, data-driven healthcare

Riyadh, Saudi Arabia – 27 October 2025: M42, a global health leader powered by artificial
intelligence (AI), technology and genomics, today announced the official incorporation of M42 Saudi
Arabia, marking a new era in its partnership with the Kingdom. The announcement was made during
the Global Health Exhibition (GHE) in Riyadh, underscoring M42’s deepening commitment to
advance the Kingdom’s Vision 2030 healthcare transformation agenda.
Building on more than 12 years of a trusted, long-term partnership with the Saudi Ministry of Health
(MoH) through the operation of over 40 Diaverum clinics across 33 cities, including Riyadh, Jeddah,
Makkah and Madinah, the establishment of M42 Saudi Arabia represents the next phase in a trusted
partnership grounded in performance, impact and shared purpose.
As part of its commitment to Saudi Arabia, M42 Saudi Arabia will continue the provision of renal care
through its Diaverum clinics and explore partnerships in advanced patient care, multi-omics,
population health programs, including metabolic and lifestyle disease management, and cutting-
edge digital integration.
With a focus on empowering Saudi talent and driving innovation through AI and technology, the
launch signals M42’s ambition to partner with the Kingdom to help realize its Vision 2030 ambition
for a future-ready, sustainable health system and support the nation’s shift toward precision,
preventive and predictive care.
Dimitris Moulavasilis, Group Chief Executive Officer at M42, said: “As the largest market in the
Middle East and North Africa region, Saudi Arabia is an important partner in the region’s healthcare
transformation. The incorporation of M42 Saudi Arabia is a natural step for us in building a globally
scaled health intelligence ecosystem that works in partnership with local institutions to shift from
reactive care to precision, prevention and prediction. With Diaverum, we have invested in Saudi
Arabia and are proud of the quality renal care services we have delivered for the Kingdom’s people.
As part of Vision 2030, we are now doubling down in the country to help create a sustainable,
integrated health ecosystem that benefits generations to come.”
Ziyad Kabli, Chief Operating Officer Middle East and Asia at M42 , added: “For more than a decade,
our work in Saudi Arabia has centered on providing high-quality renal care through Diaverum. The
launch of M42 Saudi Arabia marks our expansion from specialty services to system-wide
collaboration in precision, preventive and predictive health. We’re here to partner, invest and help
build local capabilities that will define the next chapter of Saudi Arabia’s health transformation
journey and support its ambition in tackling health challenges around the world.”
The deepening of its presence in Saudi Arabia marks M42’s continued growth in region, as part of its
continued expansion in areas of strategic priority. Similarly, M42 Saudi Arabia aims to build on its
existing footprint in the country by developing local specialty care services, partnering on omics and

Restricte
d
population health initiatives and scaling digital health solutions, as well as supporting Saudi Arabia’s
growing life sciences ambition for leadership in clinical trials and R&D. The incorporation will enable
new Saudi-led pilot programs, collaborative R&D and partnerships with government and private
health institutions, further reinforcing the Kingdom’s leadership in precision, preventive and
predictive healthcare.
M42’s track record, combined with deep local roots in Saudi Arabia through Diaverum, positions
M42 Saudi Arabia as one of the Kingdom’s most impactful international healthcare partners. Its
ambition in the Kingdom comes on the back of M42’s expanding footprint in the Middle East with
recent news on M42 launching the country’s first virtual hospital called Digital Health Centre – a
pioneering digital health initiative that connects five remote hospitals to a central command centre
in Alsalt, a city in west-central Jordan – with the Jordanian Ministry of Health and the Ministry of
Digital Economy and Entrepreneurship. In Bahrain, M42 will be providing long-term care and post-
acute rehabilitation services in Al Jasra, Bahrain in partnership with Mumtalakat through Amana
Healthcare – Bahrain.

-Ends-

About M42
M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to
advance innovation in health for people and the planet. M42 combines its specialized, state-of-the-
art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced
technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional
healthcare models and positively impact lives globally.
Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42
has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned
healthcare providers, including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial
College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu
Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu
Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.